Skip to content
type1.science
Phase 3RecruitingNCT06334133

Cadisegliatin phase 3 adjunct to insulin

vTv Therapeutics phase 3 trial testing cadisegliatin, a liver-selective glucokinase activator, as an insulin adjunct to reduce level-2/3 hypoglycemia in adults with type 1 diabetes.

Primary endpoints

  • Change in incidence of level-2 or level-3 hypoglycemia

Results so far

No results posted yet.